Loading quotes...
Forecast
The analysts' average price target is €73.79 (-2.93%). The median is €72.68 (-4.39%).
| Buy |
13 |
| Hold |
7 |
| Sell |
0 |
Discussions in the community
- Portfolio advice for 21 y.o (200k portfolio)
Hi there! I just would love some feedback and advice on how/what I could improve: About me: No Debt longterm(40+ years) 21 y.o Student: Economics Country: Austria Investing monthly 100 in Microsoft…
j jake V in Portfolio Tracking
1 12 - Probleme beim Sync mit Bonds, Bezugsrechten
Hi, ich bin neu bei Parqet und leider kommt es nach dem ING Sync zu groesseren Abweichungen. Folgende Probleme bestehen aus meiner Sicht, kennt sich damit jemand aus und weiss ggf. was zu tun ist?…
u user_362beb I in Schnack
0 2
News Go to news feed
GE Healthcare raises full-year outlook after strong third quarter
GE Healthcare reported organic revenue growth of 6.2% in the third quarter to $5.5 billion and a net income increase to $615 million. The company raised its 2026 guidance: comparable revenue growth of around 4%, adjusted EBIT margin of 15.5–15.7% and adjusted earnings per share of $4.95–5.05. CEO Peter Arduini said the improvements in results and margins were broad-based across all segments. The stock jumped significantly in early trading. » More on finanzen.net
GE HealthCare Technologies: investment one year ago would have incurred a 13.5% loss
A $1,000 investment in GE HealthCare Technologies one year ago would now be worth only $865.27, representing a loss of 13.47%. The purchase resulted in 13.473 shares; the most recently quoted closing price was $64.22. Market capitalization was last reported at $29.13 billion. Stock splits and dividends are not taken into account in the calculation. » More on finanzen.net
GE HealthCare Technologies: three-year investment down 2.77%
Had $1,000 been invested in GE HealthCare Technologies three years ago (share price then $66.28), it would have bought 15.088 shares. At the closing price of $64.45 on September 17, 2026, those would have been worth $972.31, a decline of 2.77%. The company's market value was most recently $28.62 billion; stock splits and dividends were not taken into account in the calculation. » More on finanzen.net
GE HealthCare Technologies: stock down about 17.6% in one year
A $100 investment in GE HealthCare Technologies one year ago would be worth about $82.40 today, a decline of roughly 17.6%. The stock's closing price on September 10, 2026, was $64.24. Market capitalization is reported at approximately $29.44 billion. » More on finanzen.net
GE HealthCare: order backlog grows, margins expected to rise in second half of year
GE HealthCare reports order growth of 11%, a book-to-bill of 1.15 and an order backlog of USD 2.1bn, driven mainly by service contracts. Management expects an acceleration in organic growth and a sequential margin improvement of around 250 basis points in the second half of the year, despite headwinds from tariffs, supply-chain issues and storage costs (~200 basis points). The patient care solutions division is expected to recover operationally but is under strategic review, while pharmaceutical diagnostics and new imaging products such as Photonova Spectra will support margin-rich growth. China is stabilizing after declines, but a slight decline for 2024 is still expected. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 4.87bn | 11.06% |
| Gross profit | 1.96bn | 15.79% |
| Net profit | 542.07m | 42.63% |
| EBITDA | 915.52m | 19.11% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €34.1bn |
Number of shares | 452.14m |
52-week high/low | €81.56 - €53.37 |
Dividend yield | 0.17% |
Dividends TTM | €0.13 |
Beta | 0.77 |
P/E ratio | 17.51 |
PEG ratio | -7.72 |
P/B ratio | 3.23 |
P/S ratio | 1.73 |
Company profile
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
| Name | GE HealthCare Technologies |
| CEO | Peter J. Arduini |
| Headquarters | Chicago,
il USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 27/01/2012 |
| Employees | 54,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | GEHC |
Frankfurt | L0T.F |
Düsseldorf | L0T.DU |
SIX | L0T.SW |
München | L0T.MU |